MGF (Mechano Growth Factor)

Exercise-induced IGF-1 splice variant that activates muscle satellite (stem) cells. 25% muscle mass increase in 3 weeks in animal models. Declines with age.

Overview

Also Known As

Mechano Growth Factor, IGF-1Ec, PEG-MGF (PEGylated form)

Mechanism of Action

IGF-1 splice variant E-peptide activates quiescent muscle satellite cells. Promotes proliferation (not differentiation) of muscle stem cells. Autocrine/paracrine action in exercised muscle. PEG-MGF extends half-life via PEGylation.

Product

Mechano Growth Factor, IGF-1Ec, PEG-MGF (PEGylated form) vial
Dosing & Administration
Typical protocols and routes

Half-Life

Minutes (unmodified). PEG-MGF: several days

Administration Routes

intramuscularsubcutaneous

Dosing Protocols

Reconstitute PEG-MGF 2 mg vial with 1 mL bacteriostatic water, giving 10 doses. Draw 10 units per day on insulin syringe (marked 1-100) for 10 days.
Research
Key findings and status

Key Research Findings

Goldspink et al.: characterized MGF as exercise-induced splice variant. Hill & Goldspink (2003): 25% muscle mass increase in 3 weeks. Barton (2006): MGF activates satellite cells more effectively than IGF-1Ea. Age-related expression decline documented.
Detailed Information

Mechano Growth Factor (MGF) is a splice variant of IGF-1 (specifically IGF-1Ec in humans) that is produced locally in muscle tissue in response to mechanical stress such as resistance exercise. Unlike systemic IGF-1, MGF acts in an autocrine/paracrine fashion to activate muscle satellite cells — the stem cells responsible for muscle repair and hypertrophy.

Mechanism of Action

When muscle is subjected to mechanical loading or damage, the IGF-1 gene undergoes alternative splicing to produce MGF. The MGF E-peptide (the C-terminal extension unique to this splice variant) activates quiescent satellite cells, stimulating their proliferation and fusion with existing muscle fibers. This is distinct from mature IGF-1Ea, which primarily promotes differentiation rather than proliferation. PEG-MGF is a modified form with polyethylene glycol conjugation for extended half-life.

Research

Goldspink et al. first characterized MGF as an exercise-induced IGF-1 splice variant. Hill and Goldspink (2003) showed that intramuscular MGF injection produced a 25% increase in muscle mass within 3 weeks in animal models. Barton (2006) demonstrated that MGF activates satellite cells more effectively than mature IGF-1Ea. Age-related decline in MGF expression after exercise is documented and correlates with sarcopenia.

Safety & Legal

Side Effects & Warnings

Injection site pain/soreness. Limited systemic data. Localized muscle growth effects. Long-term safety unknown.

Legal Status

Research use only
Molecular Data
Chemical properties

Molecular Weight

Approximately 2867 g/mol (E-peptide)

Amino Acid Sequence

24-amino acid E-peptide from IGF-1Ec splice variant

Quick Facts

Class

Performance

Research Status

Preclinical

Half-Life

Minutes (unmodified). PEG-MGF: several days

Routes

intramuscular
subcutaneous

Category

Performance & Body Composition